Finalist
Foundation Reinvented: A Launch Strategy That Changed the IgAN Conversation in Nephrology
Summary of work
When kidneys start to fail, everyday life becomes a balance between fatigue, fear, and the fight to stay well. For people with IgA nephropathy (IgAN), a rare autoimmune disease, diagnosis is often in their 30s or 40s, after half of their kidney function is already lost. They face constant monitoring and the looming threat of dialysis or transplant.For decades, treatment options were limited to CKD generics or steroids, but with significant side effects and limited long-term efficacy. However, in 2023, breakthrough data from novel therapies targeting both immune dysfunction and kidney damage signalled a turning point in IgAN.FILSPARI led the way as the first and only DEARA (non-immunosuppressive, nephroprotective therapy). However, success hinged on overcoming significant barriers: nephrologists’ entrenched reliance on generic treatments, low urgency to change clinical practice, and the need to establish FILSPARI’s mechanism of action as the definitive standard of care solution in a fast-moving market.Launched at ERA 2024, FILSPARI redefined the IgAN standard of care and captured the attention of nephrologists. By year-end, sales in the first launch market were 700% ahead of forecast. FILSPARI had not only claimed leadership but set a new benchmark for what IgAN treatment could, and should, be.
Judges’ comments
“Foundation Reinvented” was a confident launch that reframed the clinical conversation and met the moment. The team made proteinuria feel urgent and actionable, then used a clear visual story to anchor FILSPARI’s value. The congress execution was bold and well timed. Results are strong, especially the commercial lift and guideline momentum.
